DERMATITIS, ATOPIC
Clinical trials for DERMATITIS, ATOPIC explained in plain language.
Never miss a new study
Get alerted when new DERMATITIS, ATOPIC trials appear
Sign up with your email to follow new studies for DERMATITIS, ATOPIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Eczema drug study cut short: what we learned about abrocitinib
Disease control TerminatedThis study looked at how well the medicine abrocitinib works for adults with moderate to severe atopic dermatitis (eczema). Researchers tracked 112 people for up to 12 months to see if their skin cleared or improved. The study was stopped early, but the goal was to understand rea…
Matched conditions: DERMATITIS, ATOPIC
Sponsor: Pfizer • Aim: Disease control
Last updated May 17, 2026 04:30 UTC
-
New eczema drug shows promise but study halted early
Disease control TerminatedThis study tested an experimental drug called GSK1070806 for adults with moderate to severe atopic dermatitis (eczema) who had already tried other treatments. The goal was to see if the drug could reduce eczema severity and itching. The study was stopped early, so final results a…
Matched conditions: DERMATITIS, ATOPIC
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 17, 2026 04:29 UTC
-
Eczema drug study halted early: what we learned about Long-Term safety
Disease control TerminatedThis study tested the long-term safety of an experimental drug called GSK1070806 in adults with moderate to severe atopic dermatitis (eczema). It was designed for people who had already completed an earlier study of the same drug. The study was terminated early, so only limited s…
Matched conditions: DERMATITIS, ATOPIC
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 11, 2026 20:51 UTC